If I need to hold apixaban (Eliquis) for a prolonged period, should I start heparin (unfractionated or low‑molecular‑weight) as a bridging therapy?

Bridging with Heparin When Holding Apixaban: Not Recommended in Most Cases

For the vast majority of patients requiring prolonged interruption of apixaban, you should NOT start heparin bridging therapy. The most recent high-quality guidelines explicitly recommend against routine heparin bridging for direct oral anticoagulants (DOACs) like apixaban, as bridging increases major bleeding risk 2-3 fold without reducing thromboembolic events 1.

When to Avoid Bridging (Most Patients)

Do not bridge with heparin if:

• Patient has atrial fibrillation (even with moderate stroke risk)
• Interruption is for elective surgery or procedures
• Patient has normal to moderately impaired renal function
• The interruption period follows standard DOAC half-life principles (2-3 days for most procedures, 3-5 days for high-bleeding-risk procedures)

The 2017 French GIHP guidelines state unequivocally: "There is no need for preoperative heparin bridging (UFH or LMWH) except for very thrombotic high-risk" 1. This reflects accumulated evidence showing that bridging patients on DOACs during invasive procedures increases bleeding without reducing thromboembolism 1.

The Rare Exception: Very High Thrombotic Risk Only

Consider bridging ONLY if the patient meets ALL of these criteria:

• Mechanical heart valve (though apixaban is contraindicated in this population per FDA label 2)
• Recent VTE (within 3 months) requiring therapeutic anticoagulation
• Severe thrombophilia with history of recurrent VTE despite anticoagulation
• Active acute thrombosis requiring ongoing therapeutic anticoagulation

Even in these scenarios, the 2022 CHEST guidelines note that bridging should use therapeutic-dose LMWH (enoxaparin 1 mg/kg BID) or IV unfractionated heparin in severe renal insufficiency 3.

Practical Management Algorithm

For Standard Interruption (Low-Moderate Bleeding Risk Procedures):

1. Stop apixaban 2-3 days before procedure (last dose 48 hours pre-procedure for twice-daily dosing) 1
2. No bridging anticoagulation
3. Resume apixaban 6-24 hours post-procedure when hemostasis adequate 3, 2

For High Bleeding Risk Procedures:

1. Stop apixaban 3 days before (or 4-5 days for neuraxial procedures) 1
2. No bridging anticoagulation
3. Consider prophylactic-dose LMWH (enoxaparin 40 mg daily) starting 6-24 hours post-op for VTE prophylaxis until apixaban resumed 3
4. Resume therapeutic apixaban 24-72 hours post-procedure when surgical hemostasis confirmed 1

For Severe Renal Impairment (CrCl <30 mL/min):

1. Apixaban interruption may need extension to 4-5 days
2. If bridging deemed absolutely necessary for very high thrombotic risk, use IV unfractionated heparin (easier to reverse than LMWH in renal failure) 3

Critical Pitfalls to Avoid

Major bleeding from bridging is devastating because it requires prolonged anticoagulation interruption, paradoxically increasing thrombotic risk 3. Research shows bridging with heparin before restarting rivaroxaban (similar DOAC) increased the composite of ischemic events and major bleeding (HR 1.80) without individual benefit 4.

The FDA label for apixaban explicitly states: "Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 2. This reflects the short half-life of apixaban (approximately 12 hours), meaning anticoagulant effect dissipates within 24-48 hours without need for substitution 2.

For neuraxial procedures: The FDA warns that indwelling epidural catheters should not be removed earlier than 24 hours after last apixaban dose, and next apixaban dose should not be given earlier than 5 hours after catheter removal 2. Bridging with heparin complicates this timing and increases spinal hematoma risk.

Post-Procedure VTE Prophylaxis vs. Bridging

These are different concepts:

• Bridging = therapeutic-dose heparin to replace apixaban's anticoagulant effect (NOT recommended)
• VTE prophylaxis = prophylactic-dose LMWH for high-risk surgery (e.g., cancer surgery, orthopedic surgery) until therapeutic apixaban resumed (reasonable in select cases) 3, 1

The distinction matters: prophylactic dosing (enoxaparin 40 mg daily) carries much lower bleeding risk than therapeutic bridging (enoxaparin 1 mg/kg BID) and addresses procedure-specific VTE risk rather than attempting to maintain continuous therapeutic anticoagulation 3.